Now what's interesting is that the trial that was fully enrolled in Feruary was the COAST trial. That is the Eyelea (Aflibercept) combination which I reckon is going to be by far the tougher to achieve the primary endpoint. If that one should report success (?March/April 2025), things are going to get very interesting. I kind of though the ShORe trial would be the first to enrol. Anyway food for thought.
Hang in there!!, page-147
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $241.9M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.5¢ | $81.57K | 222.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 100385 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 137089 | 15 |
View Market Depth
| Last trade - 10.17am 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
37.0¢ |
Change
0.000 ( 0.08 %) |
||||
| Open | High | Low | Volume | ||
| 36.5¢ | 37.0¢ | 36.5¢ | 732364 | ||
| Last updated 10.46am 17/06/2024 ? | |||||
| OPT (ASX) Chart |